In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Afferent Strikes a Good Deal with Stryker

Executive Summary

In January, Stryker made an equity investment in neurostimulation start-up Afferent, operating in stroke rehabilitation. The deal is part of Stryker's growth plans to invest in emerging markets that are adjacent to core business segments. For Afferent, the partnership is validation of its unique platform, which stimulates afferent (incoming) rather than efferent (outgoing) nerve centers.

You may also be interested in...



Myomo Inc.

Myomo is capitalizing on the growing tide of scientific evidence that patients have the ability to recover motor function following neurological trauma, such as stroke. The first product from its NeuroRobotics platform is the e100 NeuroRobotic System, a lightweight robotic brace that slides onto the arm and helps improve the patient's mobility by enabling him to initiate and control movement of partially paralyzed muscles by using his own biological signals.

Intelect Medical Inc.

Intelect Medical brings together a patent portfolio from the Cleveland Clinic and Cornell's Weill Medical College, and a management team experienced in neuromodulation, to usher in a new generation of deep brain stimulation. The start-up's initial target markets are traumatic brain injury and stroke.

Where are They Now? Yesterday's Stroke Companies

In May 2000, START-UP profiled five medical device companies targeting stroke, in an article entitled "Making Progress in Stroke." We recently revisited Radiant Medical, Medivance, MicroVention, and two others to find out what went according to plan and what didn't In 2007, we have to say that there has in fact not been much progress, at least in acute ischemic stroke. Two companies dropped out, two remain active with promising programs--in clinical areas other than stroke, and one, which avoided ischemic stroke in the first place, enjoyed a nice exit.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel